Why Exicure, Inc.’s (XCUR) Stock Is Down 5.01%
As of Thursday, July 24, Exicure, Inc.’s XCUR share price has dipped by 5.01%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Commentary & Analysis
Why Exicure, Inc.’s (XCUR) Stock Is Up 5.53%
As of Wednesday, July 23, Exicure, Inc.’s XCUR share price has surged by 5.53%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Exicure, Inc.’s (XCUR) Stock Is Down 14.67%
As of Tuesday, July 22, Exicure, Inc.’s XCUR share price has dipped by 14.67%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Exicure, Inc.’s (XCUR) Stock Is Down 12.68%
As of Tuesday, July 22, Exicure, Inc.’s XCUR share price has dipped by 12.68%, which has investors questioning if this is right time to buy.Omar Beirat
Why Exicure, Inc.’s (XCUR) Stock Is Up 13.44%
As of Monday, July 21, Exicure, Inc.’s XCUR share price has surged by 13.44%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | XCUR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6.9 | $242.6 | 5% |
|
| Shares Out (Mil) | 6.4 | 54.0 | 16% |
|
| Institutional Ownership | 23.8% | 93.1% | 11% |
|
| Float (Mil) | 3.1 | 41.4 | 8% |
|
| Beta | 3.62 | 0.95 | 99% |
|
| Avg Daily Volume (000s) | 41 | 633 | 27% |
|
| Price Change (52-week) |
(80.3%) | 50.0% | 8% |
|
| Growth | XCUR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.5% | na |
|
| Net Income (5yr) | 27.6% | (10.1%) | 83% |
|
| EPS (5yr) | 55.0% | 15.8% | 94 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 43.5% | (15.7%) | 92% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | XCUR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($8) | ($44) | 30% |
|
| EPS (TTM) | ($1.302) | ($1.600) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | ($34) | 23% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $6 | $177 | 6% |
|
| Valuation | XCUR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.00 | 2.33 | 86% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | XCUR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | (55.0%) | (47.6%) | 11% |
|
| ROE | (168.4%) | (54.9%) | 5% |
|
| Liabilities to Assets | 91.4% | 29.3% | 88% |
|
| F-Score | 1 | 3 | 1% |
|
Exicure, Inc. did not pass any screens on 10/9/2026.
